Target Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Adopts stockholders rights plan in response to "increased levels of acquisition activity in the healthcare industry." The company says it is not aware of any proposed acquisition of the firm. The rights, which are exercisable 10 days after the acquisition of or tender offer for 15% or more of Target's common stock, entitle shareholders (other than the potential acquiring entity) to purchase stock, and in some cases cash or property, with a market value of twice the exercise price. The rights also allow shareholders to purchase one one-thousandth of a share of the company's Series A participating preferred stock for $135
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.